Prostate cancer cells express more androgen receptor (AR) following androgen deprivation, improving recognition by AR-specific T cells

Androgen deprivation is the primary therapy for recurrent prostate cancer, and agents targeting the androgen receptor (AR) pathway continue to be developed. Because androgen-deprivation therapy (ADT) has immmunostimulatory effects as well as direct antitumor effects, AR-targeted therapies have been...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Immunol Res
Egile Nagusiak: Olson, Brian M., Gamat, Melissa, Seliski, Joseph, Sawicki, Thomas, Jeffery, Justin, Ellis, Leigh, Drake, Charles G., Weichert, Jamey, McNeel, Douglas G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5873299/
https://ncbi.nlm.nih.gov/pubmed/29051161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-16-0390
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak